NR1H4 and metabolic dysfunction-associated steatotic liver disease: Lately the efficacies of several agents in NAFLD management, including an FXR agonist (obeticholic acid), a PPARα and PPARδ agonist (elafibrinor), a CCR2 and CCR5 antagonist (cencriviroc), or glucagon-like peptide-1 analogues (semaglutide) have been described [13,14].